![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, July 22, 2021 2:18:47 PM
As a registered nurse I am excited whenever I see new cancer treatments being developed, and I congratulate you on completing the interim analysis for your mTNBC trial with leronlimab. However, I am concerned about your recent press release from this trial. The press release is misleading regarding the benefits of the drug in the trial as well as the survival rates for mTNBC. This is causing confusion and distress among some patients and family members.
Many cancer patients are very familiar with clinical trials. They have searched for them in clinical trial databases, they have experienced them firsthand as a patient, and they have spent a great deal of time reading research studies about drugs that might help them. It is heartbreaking to see how much hope and trust they put in medical research every day. That is why it is so important that trial results be reported in a way that is both accurate and easy to understand.
Your press release announces preliminary results from 30 subjects comprised of patients in both a compassionate use study and a phase 1b/2 trial. There are only one set of results given, but the two trials have different patient populations, with different survival rates. According to ClinicalTrials.gov the compassionate use study accepts only mTNBC patients whose cancer progressed after having “been treated with >/= 3 previous chemotherapy drugs”, while the phase 1b/2 study accepts only mTNBC patients who are “untreated or naïve to chemotherapy.” Previous studies have shown two different survival rates for these different patient populations, which can differ by up to 6 months. Reporting on results combining or comparing patients from both patient populations is inaccurate and misleading.
The statement by Daniel Adams, Director of Clinical Reasearch & Development at Creatv MicroTech, Inc. is particularly distressing. He says that these women “typically have an mPFS of approximately 2 months”, and “the typical mOS in this population is only 6 to 7 months.” Imagine reading this as a chemotherapy naïve patient who has already been told by her oncologist that typical patients like her have a survival rate of 12 months or more! Adding to the confusion, you have only talked about mean survival rates in your press release, while all previous clinical trials have also reported median survival rates, to eliminate skewed results due to outliers.
I hope you will consider rescinding or amending your press release for clarity.
I wish you the best of luck as you continue your clinical trial of leronlimab for mTNBC!
Sincerely,
PB, RN
Recent CYDY News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:10 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 06/03/2024 09:10:56 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:08 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:40:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 10:15:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:16:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:30 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM